BONUS CAP-ZERTIFIKAT - ROCHE GS Share Price

Certificat

DE000VM4A0R5

Market Closed - Deutsche Boerse AG 11:21:07 31/05/2024 pm IST
278.9 EUR +0.28% Intraday chart for BONUS CAP-ZERTIFIKAT - ROCHE GS
Current month+1.16%
1 month+1.16%
Date Price Change
31/24/31 278.9 +0.28%
30/24/30 278.2 +0.76%
29/24/29 276.1 +0.35%
28/24/28 275.1 +0.09%
27/24/27 274.8 -0.03%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 11:21 pm IST

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM4A0R
ISINDE000VM4A0R5
Date issued 23/10/2023
Strike 280 CHF
Maturity 20/12/2024 (202 Days)
Parity 1 : 1
Emission price 277.4
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 290.2
Lowest since issue 270.4
Spread 3.08
Spread %1.09%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus